one-carbon Tx is specialized in targeting proteins involved in one carbon metabolism and DNA damage and repair (DDR) as a way to induce cancer cell death.
Co-founded by the Helleday Laboratory at SciLifeLab and Karolinska Institutet in Sweden, the company’s scientific idea is based on seminal research in DDR synthetic lethal biology by one of the leading research groups in the area. one-carbon Tx is developing first-in-class inhibitors targeting MTHFD2, an oncofetal protein expressed during embryogenesis, silenced in adult cells and then re-expressed in cancer. The lead program targets a range of cancer indications including leukemias and solid tumors with significant unmet medical needs and market potential.
www.one-carbon.com
Co-founded by the Helleday Laboratory at SciLifeLab and Karolinska Institutet in Sweden, the company’s scientific idea is based on seminal research in DDR synthetic lethal biology by one of the leading research groups in the area. one-carbon Tx is developing first-in-class inhibitors targeting MTHFD2, an oncofetal protein expressed during embryogenesis, silenced in adult cells and then re-expressed in cancer. The lead program targets a range of cancer indications including leukemias and solid tumors with significant unmet medical needs and market potential.
www.one-carbon.com
Investors 1
| Date | Name | Website |
| - | Eir Ventur... | eirventure... |
Mentions in press and media 4
| Date | Title | Description |
| 01.12.2025 | One-carbon Therapeutics announces oversubscribed private placement financing of SEK 153 million (€13.9 million) | One-carbon Therapeutics announces oversubscribed private placement financing of SEK 153 million (€13.9 million) Mon, Dec 01, 2025 08:00 CET Report this content Solna, Sweden, December 1, 2025. One-carbon Therapeutics AB, a clinical-stage bi... |
| 17.11.2025 | One-carbon Therapeutics AB Announces First Subject Dosed in the ODIN Phase 1/2 Clinical Study of TH9619 in Advanced Solid Tumors | One-carbon Therapeutics AB Announces First Subject Dosed in the ODIN Phase 1/2 Clinical Study of TH9619 in Advanced Solid Tumors Mon, Nov 17, 2025 08:30 CET Report this content Stockholm, Sweden. November 17th, 2025. One-carbon Therapeutics... |
| 10.06.2022 | 42 start-ups through to Catapult 2022-23 semifinals | We are excited to today announce the 42 promising start-ups that will go through to the semifinals of EIT Health Catapult 2022-23. Each year, the competition showcases Europe’s most promising biotech, medtech and digital health start-ups to... |
| - | One-carbon Therapeutics | “One-carbon therapeutics AB is tackling the most difficult to treat cancers, inflammation and autoimmune diseases by targeting the disease specific one-carbon metabolism pathway, representing a novel way of attacking the DNA damage response... |